Education
About Us
Working with TipRanks
Follow Us
Medicenna Therapeutics Corp (TSE:MDNA)
TSX:MDNA
MDNA Stock Chart & Stats
C$1.38
-C$0.01(-0.67%)
At close: 4:00 PM EST
C$1.38
-C$0.01(-0.67%)
Day’s Range― - ―
52-Week RangeC$0.78 - C$2.16
Previous CloseN/A
Volume26.49K
Average Volume (3M)30.62K
Market Cap
C$102.40M
Enterprise ValueC$49.85M
Total Cash (Recent Filing)C$20.46M
Total Debt (Recent Filing)C$162.00K
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Feb 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding68,726,980
10 Day Avg. Volume37,956
30 Day Avg. Volume30,624
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)24.28
Price to Sales (P/S)0.00
P/FCF Ratio-7.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$6.20Price Target Upside349.28% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Growth OpportunitiesPharma interest in PD1 bispecifics is increasing, indicating potential growth opportunities in this area for companies like Medicenna Therapeutics.
Market InterestRecent high-value deals in the anti-PD1 bispecifics sector suggest strong market interest and investment in similar therapeutic approaches.
Potential BenefitsThe Takeda and Innovent agreement highlights the potential of PD-1/IL-2 bispecifics, which could benefit companies involved in similar research.
Bears Say
Medicenna Therapeutics Corp News
MDNA FAQ
What was Medicenna Therapeutics Corp’s price range in the past 12 months?
Medicenna Therapeutics Corp lowest stock price was C$0.78 and its highest was C$2.16 in the past 12 months.
What is Medicenna Therapeutics Corp’s market cap?
Medicenna Therapeutics Corp’s market cap is C$102.40M.
When is Medicenna Therapeutics Corp’s upcoming earnings report date?
Medicenna Therapeutics Corp’s upcoming earnings report date is Feb 12, 2026 which is in 90 days.
How were Medicenna Therapeutics Corp’s earnings last quarter?
Medicenna Therapeutics Corp released its earnings results on Nov 13, 2025. The company reported -C$0.06 earnings per share for the quarter, missing the consensus estimate of -C$0.053 by -C$0.007.
Is Medicenna Therapeutics Corp overvalued?
According to Wall Street analysts Medicenna Therapeutics Corp’s price is currently Undervalued.
Does Medicenna Therapeutics Corp pay dividends?
Medicenna Therapeutics Corp does not currently pay dividends.
What is Medicenna Therapeutics Corp’s EPS estimate?
Medicenna Therapeutics Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicenna Therapeutics Corp have?
Medicenna Therapeutics Corp has 68,726,980 shares outstanding.
What happened to Medicenna Therapeutics Corp’s price movement after its last earnings report?
Medicenna Therapeutics Corp reported an EPS of -C$0.06 in its last earnings report, missing expectations of -C$0.053. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Medicenna Therapeutics Corp?
Currently, no hedge funds are holding shares in TSE:MDNA
Medicenna Therapeutics Corp Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.86%
12-Months-Change
Fundamentals
Return on Equity
-69.80%
Trailing 12-Months
Asset Growth
-40.12%
Trailing 12-Months
Company Description
Medicenna Therapeutics Corp
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. Its lead product is MDNA55, an interleukin- 4 (IL-4) EC that has completed Phase IIb clinical trial for the treatment of recurrent glioblastoma, as well as preclinical and clinical development stages for the treatment of other brain and non-brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.
MDNA Stock 12 Month Forecast
Average Price Target
C$6.20
▲(349.28% Upside)
Technical Analysis
Oncolytics Biotech
―
Oncolytics Biotech
―
Satellos Bioscience
―
Arch Biopartners
―
BriaCell Therapeutics
―
Eupraxia Pharmaceuticals
―
Options Prices
Currently, No data available
---